Ριλουζόλη (Greek Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ριλουζόλη" in Greek language version.

refsWebsite

Global rank Greek rank

16nih.gov

4^th place

11doi.org

2^nd place

3^rd place

2archive.org

6^th place

5^th place

2google.com

163^rd place

168^th place

1tga.gov.au

3,984^th place

2,133^rd place

1medscape.com

719^th place

579^th place

1aspetjournals.org

6,663^rd place

9,745^th place

1espacenet.com

800^th place

4,641^st place

1europa.eu

68^th place

24^th place

1springer.com

274^th place

297^th place

1worldcat.org

5^th place

8^th place

archive.org

He, Y.; Benz, A.; Fu, T.; Wang, M.; Covey, D.F.; Zorumski, C.F.; Mennerick, S. (2002). «Neuroprotective agent riluzole potentiates postsynaptic GABAA receptor function» (στα αγγλικά). Neuropharmacology 42 (2): 199–209. doi:10.1016/s0028-3908(01)00175-7. PMID 11804616. https://archive.org/details/sim_neuropharmacology_2002-02_42_2/page/199.
Wokke, J (September 21, 1996). «Riluzole.». Lancet 348 (9030): 795–9. doi:10.1016/S0140-6736(96)03181-9. PMID 8813989. https://archive.org/details/sim_the-lancet_1996-09-21_348_9030/page/795.

aspetjournals.org

jpet.aspetjournals.org

Song, JH; Huang, CS; Nagata, K; Yeh, JZ; Narahashi, T (August 1997). «Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels.». The Journal of Pharmacology and Experimental Therapeutics 282 (2): 707–14. PMID 9262334. http://jpet.aspetjournals.org/content/282/2/707.full.pdf.

doi.org

dx.doi.org

Miller, RG; Mitchell, JD; Moore, DH (March 14, 2012). «Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)». The Cochrane Database of Systematic Reviews 3 (3): CD001447. doi:10.1002/14651858.CD001447.pub3. PMID 22419278.
Bellingham, MC (February 2011). «A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?». CNS Neuroscience & Therapeutics 17 (1): 4–31. doi:10.1111/j.1755-5949.2009.00116.x. PMID 20236142.
«Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes». Eur.J.Pharmacol. 235 (2–3): 283–9. April 1993. doi:10.1016/0014-2999(93)90147-a. PMID 7685290.
He, Y.; Benz, A.; Fu, T.; Wang, M.; Covey, D.F.; Zorumski, C.F.; Mennerick, S. (2002). «Neuroprotective agent riluzole potentiates postsynaptic GABAA receptor function» (στα αγγλικά). Neuropharmacology 42 (2): 199–209. doi:10.1016/s0028-3908(01)00175-7. PMID 11804616. https://archive.org/details/sim_neuropharmacology_2002-02_42_2/page/199.
Wokke, J (September 21, 1996). «Riluzole.». Lancet 348 (9030): 795–9. doi:10.1016/S0140-6736(96)03181-9. PMID 8813989. https://archive.org/details/sim_the-lancet_1996-09-21_348_9030/page/795.
«Riluzole, a glutamate release inhibitor, and motor behavior». Naunyn Schmiedebergs Arch.Pharmacol. 358 (2): 181–90. August 1998. doi:10.1007/pl00005241. PMID 9750003.
Azbill, RD; Mu, X; Springer, JE (July 2000). «Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes». Brain Res. 871 (2): 175–80. doi:10.1016/S0006-8993(00)02430-6. PMID 10899284.
Dunlop, J; Beal McIlvain, H; She, Y; Howland, DS (March 1, 2003). «Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis». J.Neurosci. 23 (5): 1688–96. doi:10.1523/JNEUROSCI.23-05-01688.2003. PMID 12629173.
Wang, S.-J (January 2004). «Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes)». Neuroscience 125 (1): 191–201. doi:10.1016/j.neuroscience.2004.01.019. PMID 15051158.
Grant, P; Song, JY; Swedo, SE (2010). «Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder». J Child Adolesc Psychopharmacol 20 (4): 309–15. doi:10.1089/cap.2010.0009. PMID 20807069.
Harris, Elaine (2015). «Industry update: the latest developments in therapeutic delivery». Therapeutic Delivery 6 (6): 647–652. doi:10.4155/tde.15.44. ISSN 2041-5990.

espacenet.com

worldwide.espacenet.com

J.Mizoule, EP 50551 ; idem, U.S. Patent 4.370.338 (1982, 1983 both to Pharmindustrie).

europa.eu

ema.europa.eu

«Rilutek EPAR». European Medicines Agency (EMA). Ανακτήθηκε στις 1 Οκτωβρίου 2020.

google.com

J.Mizoule, EP 50551 ; idem, U.S. Patent 4.370.338 (1982, 1983 both to Pharmindustrie).
U.S. Patent 4.826.860

medscape.com

reference.medscape.com

«Rilutek (riluzole) dosing, indications, interactions, adverse effects, and more». Medscape Reference. WebMD. Ανακτήθηκε στις 18 Φεβρουαρίου 2014.

nih.gov

ncbi.nlm.nih.gov

Miller, RG; Mitchell, JD; Moore, DH (March 14, 2012). «Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)». The Cochrane Database of Systematic Reviews 3 (3): CD001447. doi:10.1002/14651858.CD001447.pub3. PMID 22419278.
Song, JH; Huang, CS; Nagata, K; Yeh, JZ; Narahashi, T (August 1997). «Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels.». The Journal of Pharmacology and Experimental Therapeutics 282 (2): 707–14. PMID 9262334. http://jpet.aspetjournals.org/content/282/2/707.full.pdf.
Bellingham, MC (February 2011). «A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?». CNS Neuroscience & Therapeutics 17 (1): 4–31. doi:10.1111/j.1755-5949.2009.00116.x. PMID 20236142.
«Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes». Eur.J.Pharmacol. 235 (2–3): 283–9. April 1993. doi:10.1016/0014-2999(93)90147-a. PMID 7685290.
He, Y.; Benz, A.; Fu, T.; Wang, M.; Covey, D.F.; Zorumski, C.F.; Mennerick, S. (2002). «Neuroprotective agent riluzole potentiates postsynaptic GABAA receptor function» (στα αγγλικά). Neuropharmacology 42 (2): 199–209. doi:10.1016/s0028-3908(01)00175-7. PMID 11804616. https://archive.org/details/sim_neuropharmacology_2002-02_42_2/page/199.
Wokke, J (September 21, 1996). «Riluzole.». Lancet 348 (9030): 795–9. doi:10.1016/S0140-6736(96)03181-9. PMID 8813989. https://archive.org/details/sim_the-lancet_1996-09-21_348_9030/page/795.
«Riluzole, a glutamate release inhibitor, and motor behavior». Naunyn Schmiedebergs Arch.Pharmacol. 358 (2): 181–90. August 1998. doi:10.1007/pl00005241. PMID 9750003.
Azbill, RD; Mu, X; Springer, JE (July 2000). «Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes». Brain Res. 871 (2): 175–80. doi:10.1016/S0006-8993(00)02430-6. PMID 10899284.
Dunlop, J; Beal McIlvain, H; She, Y; Howland, DS (March 1, 2003). «Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis». J.Neurosci. 23 (5): 1688–96. doi:10.1523/JNEUROSCI.23-05-01688.2003. PMID 12629173.
Wang, S.-J (January 2004). «Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes)». Neuroscience 125 (1): 191–201. doi:10.1016/j.neuroscience.2004.01.019. PMID 15051158.
Grant, P; Song, JY; Swedo, SE (2010). «Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder». J Child Adolesc Psychopharmacol 20 (4): 309–15. doi:10.1089/cap.2010.0009. PMID 20807069.

pubmedcentral.nih.gov

Miller, RG; Mitchell, JD; Moore, DH (March 14, 2012). «Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)». The Cochrane Database of Systematic Reviews 3 (3): CD001447. doi:10.1002/14651858.CD001447.pub3. PMID 22419278.
Bellingham, MC (February 2011). «A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?». CNS Neuroscience & Therapeutics 17 (1): 4–31. doi:10.1111/j.1755-5949.2009.00116.x. PMID 20236142.
Dunlop, J; Beal McIlvain, H; She, Y; Howland, DS (March 1, 2003). «Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis». J.Neurosci. 23 (5): 1688–96. doi:10.1523/JNEUROSCI.23-05-01688.2003. PMID 12629173.
Grant, P; Song, JY; Swedo, SE (2010). «Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder». J Child Adolesc Psychopharmacol 20 (4): 309–15. doi:10.1089/cap.2010.0009. PMID 20807069.

livertox.nih.gov

«Riluzole».

springer.com

adisinsight.springer.com

«BHV 0223 – AdisInsight». Adisinsight.springer.com. Ανακτήθηκε στις 20 Μαΐου 2016.

tga.gov.au

ebs.tga.gov.au

«PRODUCT INFORMATION RILUTEK® (riluzole) Tablets» (PDF). TGA eBusiness Services. sanofi-aventis australia pty ltd. 6 Ιανουαρίου 2009. Ανακτήθηκε στις 18 Φεβρουαρίου 2014.

worldcat.org

Harris, Elaine (2015). «Industry update: the latest developments in therapeutic delivery». Therapeutic Delivery 6 (6): 647–652. doi:10.4155/tde.15.44. ISSN 2041-5990.